Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Previous
Previous
Context Therapeutics Receives FDA Fast Track Designation for ONA-XR for PR+ Ovarian Cancer
Next
Next